Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: Current options and future directions

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 5-12

  Navada, Shyamala C ^a   Silverman, Lewis R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; AML; ASCT; Azacitidine; Decitabine; Erythropoiesis stimulating agents; ESA; Hypomethylating agents; Iron chelation therapy; Lenalidomide; MDS; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; ANTIANEMIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; DANAZOL; DEFERASIROX; DEFEROXAMINE; ELTROMBOPAG; ENTINOSTAT; EZATIOSTAT; FERRITIN; GLUTATHIONE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN; LENALIDOMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; ROMIPLOSTIM; THYMOCYTE ANTIBODY; VALPROIC ACID; VORINOSTAT;

5Q- SYNDROME; ADD ON THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; BLOOD TOXICITY; CHELATION THERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EPIGENETICS; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FERRITIN BLOOD LEVEL; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON OVERLOAD; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

COMBINED MODALITY THERAPY; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 79551501117     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0071-9     Document Type: Article

References (49)

1. Silverman LR: The myelodysplastic syndrome. In Cancer Medicine, edn 8. Edited by Hong WK, Bast RC Jr, Hait WN, et al. Shelton, CT: PMPH-USA; 2010:1544-1558.
2. SL Goldberg E Chen M Corral, et al. 2010 Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries J Clin Oncol 28 2847 2852 10.1200/JCO.2009.25.2395 20421543
3. JM Bennett D Catovsky MT Daniel, et al. 1982 Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189 199 1:STN:280:DyaL383gs1GhtQ%3D%3D 6952920
4. P Greenberg C Cox MM Lebeau, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088 1:CAS:528:DyaK2sXhvVars70%3D 9058730
5. JW Vardiman NL Harris RD Brunning 2002 The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2292 2302 1:CAS:528:DC%2BD38XnvVGisrY%3D 10.1182/blood-2002-04-1199 12239137
6. L Malcovati U Germing A Kuendgen, et al. 2005 A WHO Classification-Based Prognostic Scoring System (WPSS) for predicting survival in myelodysplastic syndromes Blood 106 788
7. AJ Jansen ML Essink-Bot EA Beckers, et al. 2003 Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes Br J Haematol 121 270 274 1:STN:280:DC%2BD3s3htlOmsA%3D%3D 10.1046/j.1365-2141. 2003.04272.x 12694248 (Pubitemid 36560593)
8. D Bowen D Culligan S Jowitt, et al. 2003 Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 187 200 10.1046/j.1365-2141.2003.03907.x 12542475 (Pubitemid 36194166)
9. DJ Pinchon SJ Stanworth C Doree, et al. 2009 Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review Am J Hematol 84 671 677 10.1002/ajh.21503 19705430
10. L Malcovati MG Della Porta C Pascutto, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making J Clin Oncol 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
11. M Cazzola L Malcovati 2005 Myelodysplastic syndromes-coping with ineffective hematopoiesis N Engl J Med 352 536 538 1:CAS:528: DC%2BD2MXhtFemsr0%3D 10.1056/NEJMp048266 15703418 (Pubitemid 40204666)
12. E Hellstrom-Lindberg L Malcovati 2008 Supportive care, growth factors, and new therapies in myelodysplastic syndromes Blood Reviews 22 75 91 18068281
13. D Metcalf 1985 The granulocyte-macrophage colony-stimulating factors Science 229 16 22 1:CAS:528:DyaL2MXksVyhtbs%3D 10.1126/science.2990035 2990035
14. P Greenberg K Taylor R Larson, et al. 1993 Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS) [abstract] Blood 82 suppl 1 196a
15. E Hellstrom-Lindberg 1995 Efficacy of erythropoietin in the myelodysplastic syndrome: a meta-analysis of 205 patients from 17 studies Br J Haematol 89 67 71 1:STN:280:DyaK2M7jsVKrsQ%3D%3D 7833279
16. E Hellstrom-Lindberg R Negrin R Stein, et al. 1997 Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model Br J Haematol 99 344 351 1:CAS:528:DyaK2sXns1OhtLo%3D 10.1046/j.1365-2141.1997.4013211.x 9375752
17. C Kelaidi P Fenaux 2010 Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond Expert Opin Biol Ther 10 605 614 1:CAS:528:DC%2BC3cXjtVyntrs%3D 10.1517/14712591003709713 20201708
18. PL Greenberg Z Sun KB Miller, et al. 2009 Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group Blood 114 2393 2400 1:CAS:528: DC%2BD1MXht1WktrzO 10.1182/blood-2009-03-211797 19564636 This study showed that ESAs are effective in improving quality of life and erythroid responses in lower-risk MDS patients
19. BD Cheson PL Greenberg JM Bennett, et al. 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419 425 1:CAS:528:DC%2BD28XntFehtrk%3D 10.1182/blood-2005-10-4149 16609072 (Pubitemid 44061337)
20. G Chan G DiVenuti K Miller 2002 Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome Am J Hematol 71 166 171 1:CAS:528:DC%2BD38XptVKltLs%3D 10.1002/ajh.10209 12410570 (Pubitemid 35253330)
21. HM Kantarjian FJ Giles PL Greenberg, et al. 2010 Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy Blood 116 3163 3170 1:CAS:528:DC%2BC3cXhsVeisLvO 10.1182/blood-2010-03-274753 20631375 This study evaluates the efficacy of romiplostim, a thrombopoietin receptor agonist, in the treatment of thrombocytopenia in patients with lower-risk MDS
22. H Kantarjian P Fenaux MA Sekeres, et al. 2010 Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia J Clin Oncol 28 437 444 1:CAS:528:DC%2BC3cXivFartLg%3D 10.1200/JCO.2009.24.7999 20008626
23. Cazzola M, Della Porta MG, Malcovati L: Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2008: 166-175.
24. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1.2011. Available at http://www.nccn.org/professionals/physician-gls/PDF/mds.pdf. Accessed September 2010.
25. P Armand HT Kim CS Cutler, et al. 2007 Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 4586 4588 1:CAS:528:DC%2BD2sXls1amtrY%3D 10.1182/blood-2006-10-054924 17234738 (Pubitemid 46743431)
26. JJ Molldrem M Caples D Mavroudis, et al. 1997 Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 99 699 705 1:STN:280:DyaK1c%2Fmt1amuw%3D%3D 10.1046/j.1365-2141.1997.4423249.x 9401087
27. JJ Molldrem E Leifer E Bahceci, et al. 2002 Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes Ann Intern Med 137 156 163 12160363
28. •• Sloand EM, Wu CO, Greenberg P, et al: Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26: 2505-2511. This study demonstrates that immunosuppressive therapy is associated with significant improvement in pancytopenia and leads to improved progression-free and overall survival in a subset of younger patients with lower-risk MDS.
29. Sloand EM, Olnes MJ, Weinstein B, et al: Alemtuzumab treatment of intermediate-1 (INT-1) myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. Blood 2009, 114: Abstract 116.
30. A List G Dewald J Bennett, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456 1465 1:CAS:528:DC%2BD28XhtVGgtrvO 10.1056/NEJMoa061292 17021321 (Pubitemid 44511560)
31. A Raza JA Reeves EJ Feldman, et al. 2008 Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 86 93 1:CAS:528:DC%2BD1cXjtVGrsw%3D%3D 10.1182/blood-2007-01-068833 17893227 This paper reports that lenalidomide has activity in transfusion-dependent lower-risk MDS patients who do not have the del(5q) abnormality
32. MA Sekeres JP Maciejewski AA Giagounidis, et al. 2008 Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes J Clin Oncol 26 5943 5949 10.1200/JCO.2007.15.5770 19018091
33. •• Fenaux P, Giagounidis A, Selleslag D, et al: RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in pts with low- or int-1 risk MDS with del5q: results from a randomized phase III trial (MDS-004) [abstract]. Blood 2009, 114: Abstract 944. This study demonstrates that lenalidomide should be started at a dose of 10 mg, which achieves better transfusion independence and cytogenetic remissions than 5 mg, while maintaining a similar toxicity profile.
34. LR Silverman EP Demakos BL Peterson, et al. 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2429 2440 1:CAS:528: DC%2BD38XksFakur8%3D 10.1200/JCO.2002.04.117 12011120 (Pubitemid 34525728)
35. P Fenauz GJ Mufti E Hellstrom-Lindberg, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study Lancet Oncol 10 223 232 10.1016/S1470-2045(09)70003-8 This landmark study demonstrated that azacitidine has a survival advantage when compared with conventional care in patients with higher-risk MDS
36. H Kantarjian JP Issa CS Rosenfeld, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803 1:CAS:528:DC%2BD28XksFCrsrk%3D 10.1002/cncr.21792 16532500
37. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groups. Blood 2008, 112: Abstract 226.
38. A Kuendgen S Knipp F Fox, et al. 2005 Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodypslastic syndrome and relapsed or refractory acute myeloid leukemia Ann Hematol 84 61 66 1:CAS:528:DC%2BD2MXht1OisrvE 10.1007/s00277-005- 0026-8 16270213
39. Garcia-Manero G, Silverman LR, Gojo I, et al. A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplastic syndromes: preliminary results [abstract]. Blood 2008, 112: Abstract 5084.
40. FR Appelbaum J Barrall R Storb, et al. 1990 Bone marrow transplantation for patients with myelodysplasia Ann Int Med 112 590 597 1:STN:280: DyaK3c3isFCqtw%3D%3D 2183666
41. CS Cutler SJ Lee P Greenberg, et al. 2004 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 1004 579 585 10.1182/blood-2004-01-0338 (Pubitemid 38900045)
42. A Kuendgen C Strupp M Aivado, et al. 2006 Myelodysplastic syndromes in patients younger than age 50 J Clin Oncol 34 5358 5365 10.1200/JCO.2006.07.5598 (Pubitemid 46623166)
43. M Sorror B Sandmaier B Storer, et al. 2007 Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 4246 4254 10.1200/JCO.2006.09.7865 17724349 (Pubitemid 47554249)
44. DM Oliansky JH Antin JM Bennett, et al. 2009 The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review Biol Blood Marrow Transplant 15 137 172 10.1016/j.bbmt.2008.12.003 19167676 This review provides treatment recommendations regarding the role and appropriate timing of ASCT in patients with MDS
45. G Garcia-Manero J Shan S Faderl, et al. 2008 A prognostic score for patients with lower risk myelodysplastic syndrome Leukemia 22 538 543 1:STN:280:DC%2BD1c7nsVKntw%3D%3D 10.1038/sj.leu.2405070 18079733 This article provides a model that predicts which patients with lower-risk MDS have worse outcomes and may benefit from early intervention (Pubitemid 351386723)
46. GJ Schiller J Slack JD Hainsworth, et al. 2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes J Clin Oncol 24 2456 2464 1:CAS:528:DC%2BD28XmtVOmsbg%3D 10.1200/JCO.2005.03.7903 16651647 (Pubitemid 46630622)
47. A Raza N Galili S Smith, et al. 2009 Phase I multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome Blood 113 6533 6540 1:CAS:528:DC%2BD1MXotlWrurg%3D 10.1182/blood-2009-01-176032 19398716
48. A Raza N Galili N Callander, et al. 2009 Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromes J Hematol Oncol 2 20 10.1186/1756-8722-2-20 19439093
49. P Fenaux A Raza GJ Mufti, et al. 2007 A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high-risk myelodysplastic syndrome Blood 109 4158 4163 1:CAS:528:DC%2BD2sXls1anu78%3D 10.1182/blood-2006-07-035725 17264294 (Pubitemid 46743377)